Latest News

  • Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics

    Leading computational physics-based platform for design and optimization of small molecules bolsters Roivant’s drug discovery capabilities Silicon Therapeutics drug discovery executives Dr. Woody Sherman, Dr. Huafeng Xu, and Dr. Chris Winter to join Roivant leadership; Drs. Sherman and Xu are industry pioneers in computationally powered drug discovery Physics-based approaches at Silicon Therapeutics to be integrated

  • Silicon Therapeutics Announces Members of Scientific Advisory Board

    BOSTON, DEC. 10, 2020 — Silicon Therapeutics, a privately-held, integrated therapeutics company with a pioneering drug discovery platform based on physics-driven molecular simulations, today announced the members of the Silicon Therapeutics scientific advisory board (SAB), which include Dr. Elliot L. Chaikof, Dr. Timothy P. Heffernan, Dr. Sun Hur, Dr. Pasi A. Jänne and Dr. Lijun Sun. The Silicon Therapeutics

  • Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma

    SNX281 is a novel systemically available small molecule agonist of Stimulator of Interferon Genes (STING) and the company’s first investigational candidate to enter the clinic The study will be comprised of two treatment arms, one evaluating SNX281 as a monotherapy, and the other evaluating SNX281 in combination with the PD-1 inhibitor pembrolizumab BOSTON, NOV. 23,

All Press Releases